Article
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
The New England journal of medicine - 16 May 2013
Jacobson Ira M, Gordon Stuart C, Kowdley Kris V, Yoshida Eric M, Rodriguez-Torres Maribel, Sulkowski Mark S, Shiffman Mitchell L, Lawitz Eric, Everson Gregory, Bennett Michael, Schiff Eugene, Al-Assi M Tarek, Subramanian G Mani, An Di, Lin Ming, McNally John, Brainard Diana, Symonds William T, McHutchison John G, Patel Keyur, Feld Jordan, Pianko Stephen, Nelson David R
Abstract excerpt
BACKGROUND: Patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3 for whom treatment with peginterferon is not an option, or who have not had a response to prior interferon treatment, currently have no approved treatment options. In phase 2 trials, regimens including the oral nucleotide polymerase inhibitor sofosbuvir have shown efficacy in patients with HCV genotype 2 or 3 infection....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.